| Drug Name |
Cortisone acetate |
| Drug ID |
BADD_D00533 |
| Description |
Cortisone acetate was first isolate in 1935 and became more widely researched in 1949.[A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203]
Cortisone acetate was granted FDA approval on 13 June 1950.[L15107] |
| Indications and Usage |
Cortisone acetate is indicated to treat a wide variety of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203] |
| Marketing Status |
approved; investigational |
| ATC Code |
H02AB10; S01BA03 |
| DrugBank ID |
DB01380
|
| KEGG ID |
D00973
|
| MeSH ID |
D003348
|
| PubChem ID |
5745
|
| TTD Drug ID |
D0X4RS
|
| NDC Product Code |
62135-173; 0220-1554; 64958-0025; 82298-129 |
| UNII |
883WKN7W8X
|
| Synonyms |
Cortisone | Cortisone Acetate | 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate | Cortone Acetate | Adreson |
